Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MRNS - Marinus Pharmaceuticals Inc


IEX Last Trade
1.42
0.020   1.408%

Share volume: 414,734
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$1.40
0.02
1.43%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
32%
Profitability 25%
Dept financing 30%
Liquidity 75%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
7.69%
1 Month
0.72%
3 Months
-4.11%
6 Months
-85.80%
1 Year
-80.03%
2 Year
-78.82%
Key data
Stock price
$1.42
P/E Ratio 
-0.52
DAY RANGE
N/A - N/A
EPS 
-$2.66
52 WEEK RANGE
$1.05 - $11.26
52 WEEK CHANGE
-$0.81
MARKET CAP 
77.118 M
YIELD 
N/A
SHARES OUTSTANDING 
55.084 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
2.06
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$376,891
AVERAGE 30 VOLUME 
$386,441
Company detail
CEO:
Region: US
Website: marinuspharma.com
Employees: 142
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides

Recent news